WO2008021136B1 - Methods and sequences to suppress primate huntington gene expression in vivo - Google Patents
Methods and sequences to suppress primate huntington gene expression in vivoInfo
- Publication number
- WO2008021136B1 WO2008021136B1 PCT/US2007/017638 US2007017638W WO2008021136B1 WO 2008021136 B1 WO2008021136 B1 WO 2008021136B1 US 2007017638 W US2007017638 W US 2007017638W WO 2008021136 B1 WO2008021136 B1 WO 2008021136B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- strand
- acid duplex
- seq
- expression
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 22
- 230000014509 gene expression Effects 0.000 title claims abstract 10
- 241000288906 Primates Species 0.000 title abstract 2
- 238000001727 in vivo Methods 0.000 title 1
- 241000282560 Macaca mulatta Species 0.000 claims abstract 6
- 241000282414 Homo sapiens Species 0.000 claims abstract 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract 3
- 102000039446 nucleic acids Human genes 0.000 claims 22
- 108020004707 nucleic acids Proteins 0.000 claims 22
- 150000007523 nucleic acids Chemical class 0.000 claims 22
- 239000002773 nucleotide Substances 0.000 claims 8
- 125000003729 nucleotide group Chemical group 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 3
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 108020003519 protein disulfide isomerase Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 108010056891 Calnexin Proteins 0.000 claims 1
- 102000034342 Calnexin Human genes 0.000 claims 1
- 101001024566 Homo sapiens Ecto-ADP-ribosyltransferase 4 Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000001159 caudate nucleus Anatomy 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000006742 locomotor activity Effects 0.000 claims 1
- 210000001577 neostriatum Anatomy 0.000 claims 1
- 210000002637 putamen Anatomy 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 102000016252 Huntingtin Human genes 0.000 abstract 1
- 108050004784 Huntingtin Proteins 0.000 abstract 1
- 230000007253 cellular alteration Effects 0.000 abstract 1
- 230000034994 death Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000006738 locomotor deficit Effects 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 230000008506 pathogenesis Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Abstract
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009523833A JP2010500025A (en) | 2006-08-09 | 2007-08-08 | Methods and sequences for suppressing primate Huntington gene expression in vivo |
EP07811178A EP2056881A4 (en) | 2006-08-09 | 2007-08-08 | Methods and sequences to suppress primate huntington gene expression in vivo |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/501,634 | 2006-08-09 | ||
US11/501,634 US7902352B2 (en) | 2005-05-06 | 2006-08-09 | Isolated nucleic acid duplex for reducing huntington gene expression |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2008021136A2 WO2008021136A2 (en) | 2008-02-21 |
WO2008021136A3 WO2008021136A3 (en) | 2008-07-03 |
WO2008021136B1 true WO2008021136B1 (en) | 2008-08-07 |
Family
ID=39082580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/017638 WO2008021136A2 (en) | 2006-08-09 | 2007-08-08 | Methods and sequences to suppress primate huntington gene expression in vivo |
Country Status (5)
Country | Link |
---|---|
US (1) | US7902352B2 (en) |
EP (1) | EP2056881A4 (en) |
JP (1) | JP2010500025A (en) |
CN (1) | CN101557831A (en) |
WO (1) | WO2008021136A2 (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080274989A1 (en) * | 2002-08-05 | 2008-11-06 | University Of Iowa Research Foundation | Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof |
US20050042646A1 (en) * | 2002-08-05 | 2005-02-24 | Davidson Beverly L. | RNA interference suppresion of neurodegenerative diseases and methods of use thereof |
US20040241854A1 (en) | 2002-08-05 | 2004-12-02 | Davidson Beverly L. | siRNA-mediated gene silencing |
US8680063B2 (en) | 2003-09-12 | 2014-03-25 | University Of Massachusetts | RNA interference for the treatment of gain-of-function disorders |
ES2808561T3 (en) * | 2003-09-12 | 2021-03-01 | Univ Massachusetts | RNA interference for the treatment of gain-of-function disorders |
WO2006121960A2 (en) * | 2005-05-06 | 2006-11-16 | Medtronic, Inc. | Methods and sequences to suppress primate huntington gene expression |
WO2007022506A2 (en) | 2005-08-18 | 2007-02-22 | University Of Massachusetts | Methods and compositions for treating neurological disease |
US8227592B2 (en) * | 2006-11-29 | 2012-07-24 | University Of Iowa Research Foundation | Alternative export pathways for vector expressed RNA interference |
US8258286B2 (en) | 2007-04-26 | 2012-09-04 | University Of Iowa Research Foundation | Reduction of off-target RNA interference toxicity |
US20090036395A1 (en) | 2007-04-26 | 2009-02-05 | Davidson Beverly L | Rna interference suppression of neurodegenerative diseases and methods of use thereof |
WO2008143774A2 (en) * | 2007-05-01 | 2008-11-27 | University Of Massachusetts | Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy |
JP2010533170A (en) | 2007-07-12 | 2010-10-21 | プロセンサ テクノロジーズ ビー.ブイ. | Molecules for targeting compounds to various selected organs, tissues or tumor cells |
WO2009054725A2 (en) | 2007-10-26 | 2009-04-30 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
WO2010002160A2 (en) | 2008-06-30 | 2010-01-07 | 조아제약주식회사 | Gene of porcine alpha-s1 casein, a promoter of the same and use thereof |
KR101881596B1 (en) | 2008-12-02 | 2018-07-24 | 웨이브 라이프 사이언시스 재팬 인코포레이티드 | Method for the synthesis of phosphorous atom modified nucleic acids |
JP2012524540A (en) | 2009-04-24 | 2012-10-18 | プロセンサ テクノロジーズ ビー.ブイ. | Oligonucleotides containing inosine for treating DMD |
IN2012DN00720A (en) | 2009-07-06 | 2015-06-19 | Ontorii Inc | |
US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
US9181544B2 (en) | 2011-02-12 | 2015-11-10 | University Of Iowa Research Foundation | Therapeutic compounds |
BR112014001244A2 (en) | 2011-07-19 | 2017-02-21 | Wave Life Sciences Pte Ltd | methods for the synthesis of functionalized nucleic acids |
ES2907250T3 (en) | 2012-01-27 | 2022-04-22 | Biomarin Tech Bv | RNA-modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy |
BR112015000784A8 (en) | 2012-07-13 | 2018-04-03 | Wave Life Sciences Japan | ASYMMETRICAL AUXILIARY GROUP |
EP2873674B1 (en) | 2012-07-13 | 2020-05-06 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
EP2872147B1 (en) | 2012-07-13 | 2022-12-21 | Wave Life Sciences Ltd. | Method for making chiral oligonucleotides |
JPWO2015108048A1 (en) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | Chiral nucleic acid adjuvant and antitumor agent having antitumor activity |
JPWO2015108046A1 (en) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | Chiral nucleic acid adjuvant and antiallergic agent having antiallergic action |
WO2015108047A1 (en) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
KR20230152178A (en) | 2014-01-16 | 2023-11-02 | 웨이브 라이프 사이언시스 리미티드 | Chiral design |
EP3146051B8 (en) | 2014-05-20 | 2019-11-27 | University of Iowa Research Foundation | Huntington's disease therapeutic compounds |
KR20170110149A (en) | 2015-02-10 | 2017-10-10 | 젠자임 코포레이션 | Mutant RNAi |
MA43072A (en) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
MA45270A (en) | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
CA3076191A1 (en) | 2017-09-22 | 2019-03-28 | Genzyme Corporation | Variant rnai |
Family Cites Families (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
GB2181691B (en) | 1985-10-21 | 1990-05-23 | Porvair Ltd | Gloves |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US5702716A (en) | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
WO1992020400A1 (en) | 1991-05-24 | 1992-11-26 | Sumitomo Pharmaceuticals Company, Limited | Instrument for applying pharmaceutical to inside of brain |
US5236908A (en) | 1991-06-07 | 1993-08-17 | Gensia Pharmaceuticals, Inc. | Methods of treating injury to the central nervous system |
US5354326A (en) | 1993-01-27 | 1994-10-11 | Medtronic, Inc. | Screening cable connector for interface to implanted lead |
CA2169292C (en) | 1993-08-12 | 2010-11-23 | E. Edward Baetge | Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules |
WO1995005864A1 (en) | 1993-08-27 | 1995-03-02 | Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Convection-enhanced drug delivery |
US5849995A (en) | 1993-09-27 | 1998-12-15 | The University Of British Columbia | Mouse model for Huntington's Disease and related DNA sequences |
US5624803A (en) | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
US6087171A (en) | 1993-12-17 | 2000-07-11 | Spinal Cord Society | Method for inducing DNA synthesis in neurons |
CA2187626C (en) | 1994-04-13 | 2009-11-03 | Michael G. Kaplitt | Aav-mediated delivery of dna to cells of the nervous system |
US6294202B1 (en) | 1994-10-06 | 2001-09-25 | Genzyme Corporation | Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers |
US5534350A (en) | 1994-12-28 | 1996-07-09 | Liou; Derlin | Powerfree glove and its making method |
AU5545596A (en) | 1995-04-28 | 1996-11-18 | Medtronic, Inc. | Intraparenchymal infusion catheter system |
US7069634B1 (en) | 1995-04-28 | 2006-07-04 | Medtronic, Inc. | Method for manufacturing a catheter |
US5840059A (en) | 1995-06-07 | 1998-11-24 | Cardiogenesis Corporation | Therapeutic and diagnostic agent delivery |
US5942455A (en) | 1995-11-14 | 1999-08-24 | Drexel University | Synthesis of 312 phases and composites thereof |
JPH09268067A (en) | 1996-03-29 | 1997-10-14 | Asahi Glass Co Ltd | Production of silicon carbide member |
US5735814A (en) | 1996-04-30 | 1998-04-07 | Medtronic, Inc. | Techniques of treating neurodegenerative disorders by brain infusion |
US7189222B2 (en) | 1996-04-30 | 2007-03-13 | Medtronic, Inc. | Therapeutic method of treatment of alzheimer's disease |
WO2000062828A1 (en) | 1996-04-30 | 2000-10-26 | Medtronic, Inc. | Autologous fibrin sealant and method for making the same |
US5976109A (en) | 1996-04-30 | 1999-11-02 | Medtronic, Inc. | Apparatus for drug infusion implanted within a living body |
WO1998012311A2 (en) | 1996-09-11 | 1998-03-26 | The General Hospital Corporation | Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell |
US5882561A (en) | 1996-11-22 | 1999-03-16 | Drexel University | Process for making a dense ceramic workpiece |
GB9701684D0 (en) | 1997-01-28 | 1997-03-19 | Smithkline Beecham Plc | Novel compounds |
US5968059A (en) | 1997-03-06 | 1999-10-19 | Scimed Life Systems, Inc. | Transmyocardial revascularization catheter and method |
GB9706463D0 (en) | 1997-03-27 | 1997-05-14 | Medical Res Council | A model of inflamation in the central nervous system for use in the study of disease |
NZ333334A (en) | 1997-04-17 | 2001-06-29 | Frank L Sorgi | Delivery system for gene therapy to the brain |
US5782892A (en) | 1997-04-25 | 1998-07-21 | Medtronic, Inc. | Medical lead adaptor for external medical device |
US5931861A (en) | 1997-04-25 | 1999-08-03 | Medtronic, Inc. | Medical lead adaptor having rotatable locking clip mechanism |
US6042579A (en) * | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
US6110459A (en) | 1997-05-28 | 2000-08-29 | Mickle; Donald A. G. | Transplants for myocardial scars and methods and cellular preparations |
US20050282198A1 (en) | 1997-05-29 | 2005-12-22 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype |
US6231969B1 (en) | 1997-08-11 | 2001-05-15 | Drexel University | Corrosion, oxidation and/or wear-resistant coatings |
US6187906B1 (en) | 1997-08-11 | 2001-02-13 | Aukland Uniservices Limited | Methods to improve neural outcome |
WO1999018792A1 (en) | 1997-10-10 | 1999-04-22 | Johns Hopkins University | Gene delivery compositions and methods |
US6151525A (en) | 1997-11-07 | 2000-11-21 | Medtronic, Inc. | Method and system for myocardial identifier repair |
DE19938960A1 (en) | 1998-03-10 | 2001-02-22 | Bisping Hans Juergen | Test cable connecting probe to test apparatus, e.g. for testing implanted pacemaker, electrotherapy or electro-diagnostics includes crocodile clip and flexible conductor with spring contact |
US6436392B1 (en) | 1998-05-20 | 2002-08-20 | University Of Iowa Research Foundation | Adeno-associated virus vectors |
PT1080202E (en) | 1998-05-27 | 2006-05-31 | Avigen Inc | DISTRIBUTION OF AAV VECTORS ENCODING AADC INTENSIFIED BY CONVECTION |
US6245884B1 (en) | 1998-10-16 | 2001-06-12 | Vivian Y. H. Hook | Secretases related to alzheimer's dementia |
US6313268B1 (en) | 1998-10-16 | 2001-11-06 | Vivian Y. H. Hook | Secretases related to Alzheimer's dementia |
US6319905B1 (en) | 1998-12-29 | 2001-11-20 | Cell Genesys, Inc. | Method of controlling L-Dopa production and of treating dopamine deficiency |
US6835194B2 (en) | 1999-03-18 | 2004-12-28 | Durect Corporation | Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners |
US6291243B1 (en) | 1999-04-28 | 2001-09-18 | The Board Of Trustees Of The Leland Stanford Jr. University | P element derived vector and methods for its use |
GB9928248D0 (en) | 1999-12-01 | 2000-01-26 | Gill Steven S | An implantable guide tube for neurosurgery |
US6310048B1 (en) | 1999-12-09 | 2001-10-30 | St. Louis University | Antisense modulation of amyloid beta protein expression |
US6461989B1 (en) | 1999-12-22 | 2002-10-08 | Drexel University | Process for forming 312 phase materials and process for sintering the same |
US20030092003A1 (en) | 1999-12-29 | 2003-05-15 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of Alzheimer's disease |
US20070026394A1 (en) | 2000-02-11 | 2007-02-01 | Lawrence Blatt | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies |
US20050032733A1 (en) | 2001-05-18 | 2005-02-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA) |
CA2400172C (en) | 2000-02-28 | 2010-04-20 | Genesegues, Inc. | Nanocapsule encapsulation system and method |
US6468524B1 (en) | 2000-03-22 | 2002-10-22 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | AAV4 vector and uses thereof |
US6551290B1 (en) | 2000-03-31 | 2003-04-22 | Medtronic, Inc. | Catheter for target specific drug delivery |
US6945969B1 (en) | 2000-03-31 | 2005-09-20 | Medtronic, Inc. | Catheter for target specific drug delivery |
US6372250B1 (en) | 2000-04-25 | 2002-04-16 | The Regents Of The University Of California | Non-invasive gene targeting to the brain |
US20020042388A1 (en) | 2001-05-01 | 2002-04-11 | Cooper Mark J. | Lyophilizable and enhanced compacted nucleic acids |
US20030190635A1 (en) | 2002-02-20 | 2003-10-09 | Mcswiggen James A. | RNA interference mediated treatment of Alzheimer's disease using short interfering RNA |
AU2001288317A1 (en) | 2000-08-30 | 2002-03-13 | Agion Technologies, Llc | Bi-laminar, hyaluronan coatings with silver-based anti-microbial properties |
US20050209179A1 (en) | 2000-08-30 | 2005-09-22 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
US6659995B1 (en) | 2000-11-17 | 2003-12-09 | Syde A. Taheri | Autologous myocyte micro granual retrieval and implantation (AMMGRI) |
CA2327208A1 (en) | 2000-11-30 | 2002-05-30 | The Government Of The United States Of America | Methods of increasing distribution of therapeutic agents |
CZ308053B6 (en) | 2000-12-01 | 2019-11-27 | Max Planck Gesellschaft | Isolated double-stranded RNA molecule, process for producing it and its use |
US7182944B2 (en) | 2001-04-25 | 2007-02-27 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of increasing distribution of nucleic acids |
US20030095958A1 (en) | 2001-04-27 | 2003-05-22 | Bhisetti Govinda R. | Inhibitors of bace |
US20050191638A1 (en) | 2002-02-20 | 2005-09-01 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
US20050282188A1 (en) | 2001-05-18 | 2005-12-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
US20050277133A1 (en) | 2001-05-18 | 2005-12-15 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
CN100424182C (en) | 2001-06-15 | 2008-10-08 | 白介素遗传公司 | Methods for detecting and treating the early onset of aging-related conditions |
CA2455424A1 (en) | 2001-08-07 | 2003-02-20 | University Of Delaware | Compositions and methods for the prevention and treatment of huntington's disease |
US6944497B2 (en) | 2001-10-31 | 2005-09-13 | Medtronic, Inc. | System and method of treating stuttering by neuromodulation |
US8274559B2 (en) * | 2001-11-09 | 2012-09-25 | Karl Storz Imaging, Inc. | Replaceable hardware component of a camera control unit for video systems |
US20030120282A1 (en) | 2001-12-24 | 2003-06-26 | Scouten Charles W. | Stereotaxic manipulator with retrofitted linear scales and digital display device |
US7294504B1 (en) | 2001-12-27 | 2007-11-13 | Allele Biotechnology & Pharmaceuticals, Inc. | Methods and compositions for DNA mediated gene silencing |
US20050096284A1 (en) | 2002-02-20 | 2005-05-05 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
US7270653B2 (en) | 2002-02-20 | 2007-09-18 | Abbott Research Group | Methods of treating abnormal biological conditions using metal oxides |
US20030224512A1 (en) | 2002-05-31 | 2003-12-04 | Isis Pharmaceuticals Inc. | Antisense modulation of beta-site APP-cleaving enzyme expression |
US20040023855A1 (en) | 2002-04-08 | 2004-02-05 | John Constance M. | Biologic modulations with nanoparticles |
US20040018520A1 (en) | 2002-04-22 | 2004-01-29 | James Thompson | Trans-splicing enzymatic nucleic acid mediated biopharmaceutical and protein |
US7008403B1 (en) | 2002-07-19 | 2006-03-07 | Cognitive Ventures Corporation | Infusion pump and method for use |
WO2004010787A1 (en) | 2002-07-25 | 2004-02-05 | Nissei Kabushiki Kaisha | Roll cone manufacturing device |
US20050106731A1 (en) | 2002-08-05 | 2005-05-19 | Davidson Beverly L. | siRNA-mediated gene silencing with viral vectors |
US20050042646A1 (en) | 2002-08-05 | 2005-02-24 | Davidson Beverly L. | RNA interference suppresion of neurodegenerative diseases and methods of use thereof |
US20050255086A1 (en) | 2002-08-05 | 2005-11-17 | Davidson Beverly L | Nucleic acid silencing of Huntington's Disease gene |
US20040023390A1 (en) | 2002-08-05 | 2004-02-05 | Davidson Beverly L. | SiRNA-mediated gene silencing with viral vectors |
US20040241854A1 (en) | 2002-08-05 | 2004-12-02 | Davidson Beverly L. | siRNA-mediated gene silencing |
JP2006507841A (en) * | 2002-11-14 | 2006-03-09 | ダーマコン, インコーポレイテッド | Functional and ultrafunctional siRNA |
US20040265849A1 (en) | 2002-11-22 | 2004-12-30 | Applera Corporation | Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof |
US7605249B2 (en) * | 2002-11-26 | 2009-10-20 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US20050048641A1 (en) | 2002-11-26 | 2005-03-03 | Medtronic, Inc. | System and method for delivering polynucleotides to the central nervous system |
US7829694B2 (en) | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
JP2004232811A (en) | 2003-01-31 | 2004-08-19 | Hitachi Unisia Automotive Ltd | Electromagnetic clutch for driving auxiliary machine |
US8946151B2 (en) | 2003-02-24 | 2015-02-03 | Northern Bristol N.H.S. Trust Frenchay Hospital | Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen |
US20040186528A1 (en) | 2003-03-20 | 2004-09-23 | Medtronic, Inc. | Subcutaneous implantable medical devices with anti-microbial agents for chronic release |
US8512290B2 (en) | 2003-03-20 | 2013-08-20 | Boston Scientific Scimed, Inc. | Devices and methods for delivering therapeutic or diagnostic agents |
US20040198640A1 (en) | 2003-04-02 | 2004-10-07 | Dharmacon, Inc. | Stabilized polynucleotides for use in RNA interference |
US20040258666A1 (en) | 2003-05-01 | 2004-12-23 | Passini Marco A. | Gene therapy for neurometabolic disorders |
EP1620133B1 (en) | 2003-05-01 | 2015-12-09 | Genzyme Corporation | Gene therapy for neurometabolic disorders |
US7917228B2 (en) | 2003-05-13 | 2011-03-29 | Medtronic, Inc. | Medical lead adaptor assembly |
AU2004239114B2 (en) | 2003-05-14 | 2008-03-13 | Japan Science And Technology Agency | Inhibition of the expression of huntingtin gene |
US20060014165A1 (en) | 2003-07-14 | 2006-01-19 | Decode Genetics Ehf. | Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association |
ES2808561T3 (en) | 2003-09-12 | 2021-03-01 | Univ Massachusetts | RNA interference for the treatment of gain-of-function disorders |
WO2005065242A2 (en) | 2003-12-29 | 2005-07-21 | Am Biosolutions | Method of treating cancer using platelet releasate |
US20050153353A1 (en) | 2004-01-09 | 2005-07-14 | Bernd Meibohm | Real-time polymerase chain reaction-based genotyping assay for beta2-adrenergic receptor single nucleotide polymorphism |
US20050202075A1 (en) | 2004-03-12 | 2005-09-15 | Pardridge William M. | Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers |
US7498316B2 (en) | 2004-04-06 | 2009-03-03 | University Of Massachusetts | Methods and compositions for treating gain-of-function disorders using RNA interference |
EP1735443A2 (en) | 2004-04-14 | 2006-12-27 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA) |
CA2566286A1 (en) * | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same |
WO2006022639A1 (en) | 2004-07-21 | 2006-03-02 | Applera Corporation | Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof |
EP1807157A2 (en) | 2004-10-22 | 2007-07-18 | Neurologix, Inc. | Use of apoptosis inhibiting compounds in degenerative neurological disorders |
NL1028134C2 (en) | 2005-01-27 | 2006-07-31 | Sara Lee De Nv | Method for preparing a drink suitable for consumption from at least two ingredients to be dissolved and / or extracted and an amount of liquid. |
TW200635542A (en) | 2005-04-01 | 2006-10-16 | Dharma Drum Mountain | Method of establishing and using commemorative material |
WO2006121960A2 (en) * | 2005-05-06 | 2006-11-16 | Medtronic, Inc. | Methods and sequences to suppress primate huntington gene expression |
US20080280843A1 (en) | 2006-05-24 | 2008-11-13 | Van Bilsen Paul | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
GB0520235D0 (en) | 2005-10-05 | 2005-11-16 | Astrazeneca Ab | Method |
AU2006305886C1 (en) * | 2005-10-28 | 2011-03-17 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of huntingtin gene |
AR059037A1 (en) | 2006-01-17 | 2008-03-12 | Schering Corp | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS |
US20080039415A1 (en) | 2006-08-11 | 2008-02-14 | Gregory Robert Stewart | Retrograde transport of sirna and therapeutic uses to treat neurologic disorders |
CN200970210Y (en) | 2006-10-12 | 2007-11-07 | 王会才 | Cleaning and dewatering machine for mop |
-
2006
- 2006-08-09 US US11/501,634 patent/US7902352B2/en not_active Expired - Fee Related
-
2007
- 2007-08-08 WO PCT/US2007/017638 patent/WO2008021136A2/en active Application Filing
- 2007-08-08 JP JP2009523833A patent/JP2010500025A/en active Pending
- 2007-08-08 CN CNA2007800372445A patent/CN101557831A/en active Pending
- 2007-08-08 EP EP07811178A patent/EP2056881A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP2056881A4 (en) | 2010-10-20 |
US20100325746A9 (en) | 2010-12-23 |
CN101557831A (en) | 2009-10-14 |
JP2010500025A (en) | 2010-01-07 |
US20070261126A1 (en) | 2007-11-08 |
WO2008021136A2 (en) | 2008-02-21 |
WO2008021136A3 (en) | 2008-07-03 |
EP2056881A2 (en) | 2009-05-13 |
US7902352B2 (en) | 2011-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008021136B1 (en) | Methods and sequences to suppress primate huntington gene expression in vivo | |
EP2049664B1 (en) | Single stranded oligonucleotides complementary to repetitive elements for treating DNA repeat instability associated genetic disorders | |
AU2015272128B2 (en) | Antisense oligonucleotides useful in treatment of Pompe disease | |
JP2024045199A (en) | Antisense oligomers for the treatment of conditions and diseases | |
WO2006121960B1 (en) | Methods and sequences to suppress primate huntington gene expression | |
JP2010500025A5 (en) | ||
EP2516647B1 (en) | Molecule for treating an inflammatory disorder | |
JP2016528890A (en) | Therapeutic use of genome editing using the CRISPR / Cas system | |
WO2008109452B1 (en) | Nucleic acid compounds for inhibiting tie gene expression and uses thereof | |
CA2526893A1 (en) | Inhibition of the expression of huntingtin gene | |
CA2847664A1 (en) | Antisense oligonucleotides for the treatment of leber congenital amaurosis | |
JP2022544702A (en) | Compositions and methods for modulating splicing and protein expression | |
JP2012503493A5 (en) | ||
US9353169B2 (en) | Means and methods for modulating NOTCH3 protein expression and/or the coding region of NOTCH3; compositions and use thereof in the treatment of CADASIL | |
EP2576782B1 (en) | Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions | |
JP2022528487A (en) | Oligonucleotide-based regulation of C9orf72 | |
JP2023552602A (en) | Therapeutic agents for the treatment of neurodegenerative disorders | |
WO2018152523A1 (en) | Use of trinucleotide repeat rnas to treat cancer | |
CA3067333A1 (en) | Enzymatic replacement therapy and antisense therapy for pompe disease | |
AU2015416656B2 (en) | Enzymatic replacement therapy and antisense therapy for Pompe disease | |
WO2022212208A1 (en) | Oligonucleotides for syngr-3 modulation | |
WO2022031591A2 (en) | Oligonucleotides for htt-1a modulation | |
EP4051794A1 (en) | Allele-specific silencing therapy for dfna9 using antisense oligonucleotides | |
Konieczny et al. | Modified antisense oligonucleotides and their analogs in therapy of neuromuscular diseases | |
WO2008109492B1 (en) | Nucleic acid compounds for inhibiting igf1r gene expression and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780037244.5 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009523833 Country of ref document: JP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07811178 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007811178 Country of ref document: EP |